prostate Case presentation

- Mr.XYZ, a 62 year old male from Bangalore had come with,
- H/O urgency for micturition 1 year.
- H/O Persistant nocturia 4 months.
- No other comorbid conditions.

ON EXAMINATION:

- A well built and well nourished man in his 7th decade
- No pallor, non icteric.
- No cyanosis, no clubbing.
- No Gen lymphadenopathy.
- No pedal edema.

- <u>P/A</u>: soft,non tender, no organomegaly.
- Ext. genitalia : Normal.
- <u>P/R</u>: (DRE)

A nodule of about 1.5 cm diameter palpable on the posterior aspect of prostate. Rectal lumen was narrowed.

Routine blood and urine investigations

- Hb 13.4 gm%
- Normal.
- <u>PSA</u> done on 31.10.2007. = 4.61 ng/dl.

Inference?

- Age adjusted PSA is abnormal.
- ?BPH
- ?Malignancy

- TRUS guided needle biopsy of the prostate: (22.12.07) performed with an 18G needle mounted on a spring loaded gun directed by ultrasound.
- MODERATELY DIFFERENTIATED ADENOCARCINOMA.
- Gleason's score=3 + 3 = 6.

CT scan of pelvis(9.11.07)

- Both lateral lobes slightly enlarged measuring 3.2 X 4.5 cm.
- A single nodule of size 2.1 X 2.4 cm located posteriorly in subcapsular location.
- seminal vesicle –Normal
- No nodes enlarged.



- STAGE T2cNoMo adenocarcinoma of prostate.
- PSA< 10
- Risk stratification.

Intermediate risk: T2b/T2c or Gleason 7 or PSA 10-20ng/dl.

Radical prostatectomy+pelvic node dissection if predicted probability of lymph node metastasis is >= 7%

WHAT NEXT?

- Organ Confined Disease.
- surgery . . . ?
- RT ...?

Intermediate risk: T2b/T2c or Gleason 7 or PSA 10-20ng/dl.

Radical prostatectomy+pelvic node dissection if predicted probability of lymph node metastasis is >= 7%

	TABLE IV.	TABLE IV. Clinical Stage T2c (palpable on both lobes)	T2c (palpabl	e on both lob	es)	
PSA				Gleason Score		
(ng/mL)	Pathologic Stage	2-4	9-5	3+4=7	4+3=7	8-10
0-2.5	Organ confined	86 (71–97)	73 (63-81)	51 (38-63)	39 (26-54)	34 (21-48)
	Extraprostatic extension	14 (3-29)	24 (17–33)	36 (26-48)	45 (32–59)	47 (33-61)
	Seminal vesicle (+)	I	1 (0-4)	5 (1–13)	5 (1-12)	8 (2-19)
	Lymph node (+)	I	1 (0-4)	6 (0-18)	9 (0-26)	10 (0-27)
2.6-4.0	Organ confined	78 (58–94)	61 (50-70)	38 (27–50)	27 (18-40)	23 (14-34)
	Extraprostatic extension	22 (6–42)	36 (27–45)	48 (37–59)	57 (44–70)	57 (44–70)
	Seminal vesicle (+)	I	2 (1–5)	8 (2-17)	6 (2–16)	10 (3-22)
	Lymph node (+)	ı	1 (0-4)	5 (0-15)	7 (0-21)	8 (0-22)
4.1-6.0	Organ confined	73 (52–93)	25 (44-64)	31 (23-41)	21 (14-31)	18 (11–28)
	Extraprostatic extension	27 (7–48)	40 (32–50)	20 (40-60)	57 (43–68)	57 (43–70)
	Seminal vesicle (+)	I	2 (1–4)	6 (2-11)	4 (1–10)	7 (2–15)
	Lymph node (+)	I	3 (1–7)	12 (5–23)	16 (6–32)	16 (6–33)
6.1-10.0	Organ confined	67 (45–91)	46 (36–56)	24 (17–32)	16 (10–24)	13 (8-20)
	Extraprostatic extension	33 (9–55)	46 (37–55)	52 (42-61)	28 (46-69)	26 (43–69)
	Seminal vesicle (+)	I	5 (2–9)	13 (6–23)	11 (4–21)	16 (6–29)
	Lymph node (+)	I	3 (1–6)	10 (5–18)	13 (6–25)	13 (5-26)
>10.0	Organ confined	54 (32–85)	30 (21–38)	11 (7-17)	7 (4–12)	6 (3–10)
	Extraprostatic extension	46 (15–68)	51 (42–60)	42 (30–55)	43 (29–59)	41 (27–57)
	Seminal vesicle (+)	I	6 (2–12)	13 (6–24)	10 (3-20)	15 (5-28)
	Lymph node (+)	I	13 (6-22)	33 (18–49)	38 (20–58)	38 (20-59)


KET: PSA = prostate-specific antigen.

• ROACH FORMULA = 2/3 of $4.61 + \{ (GS-6)X \text{ 10} \}$ = 3.07%

- Patient underwent <u>RADICAL PROSTATECTOMY</u> without lymph node dissection on o6.01.08.
- Post OP HPE:
- MODERATELY DIFFERENTIATED
 ADENOCARCINOMA/Gleason's score=3 +3= 6.
- Tumour invading the capsule with **periprostatic fat involvement with perineural involvement**.
- seminal vesicles, apex and base of prostate free .

Bone scan(04.02.07)

- Normal study.
- No metastatic foci detected.
- PSA done on 04.03.07= 0.3 ng/dl.



ADJUVANT TREATMENT?

- pT3aNxMo
- Adjuvant RT?
- Observe?
- Hormonal management?

Intermediate risk: T2b/T2c or Gleason 7 or PSA 10-20ng/dl.

Radical prostatectomy+pelvic node dissection if predicted probability of lymph node metastasis is >= 7%

If Radical prostatectomy + positive margins

- RT.
- Observe.

If Radical prostatectomy +Lymph Node Metastasis

- Androgen
 Deprivation therapy.
- Observe.

P Voluo 6 £ S Surgary Alono O.D Ş ž = و ج Surgory Alono (%) 3 £ OSWA Table 1 Randomised Trials of Adjurant Radiotherapy to the Prostate Sed After Radical Prostate termy ŝ 2 £ Adjuvent XRT (S) OS With Adjuvant XRT CO DMFS 3 £ With 9 2,5 P Value . 8 8. 8 8 Surgory Alono (%) FFBF WR 62.6 349 ŝ Adjuvant XRT CO FFBF 74.0 With 3 20 Ron domization 60 Gy to prostate Trontmont 60 to 64 Gy v 80,08 bed v Obs Potionts Мо. о 8 8 45 SWOGI EORTC* Tripl

summary

- A man in his 7th decade of life in his best quartile of health.
- diagnosed clinically as organ confined prostate cancer/PSA<10 / GS=3+3=6.
- RADICAL PROSTATECTOMY with out PLND.
- Post OP HPE pT3NxMo. (with ECE)
- Role of Adjuvant treatment?
- F/U PSA + DRE.

